News Center

Home page

Peak Report

News reports

Announcement on the 2018 Profit Distribution Plan

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviations: Jianfeng Group No.: Pro 2019-015

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on 2018 Profit Distribution Plan

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Important Content Note:

l Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company") 2018 Profit Distribution Plan is based on 2018 year-end share capital ,344,083, 828 shares, cash dividends 3.0 yuan (tax included) are distributed for every 10 shares, and the total cash dividends to all shareholders registered on the equity registration date are 103,225,148.40 yuan (tax included).

l Review Procedure: This profit distribution plan has been reviewed and approved at the 10th meeting of the 10th Board of Directors of the Company, and still needs to be submitted to the 2018 Annual General Meeting of Shareholders of the Company for review.

1. 2018 The main contents of the profit distribution plan

are audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of 2018 is ,588,502,101.59 yuan. Net profit in accounting statement of parent company ,433,675,496.73 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 43,367,549.67 yuan, plus undistributed profit 658,978,622.43 yuan at the beginning of the year, minus 2017 annual cash dividend 34,408,382.80 yuan, and the distributable profit for this year is 1,014,878,186.69 yuan.

Company plans to make cash distribution in 2018 . Based on 2018 year-end share capital ,344,083, 828 shares, it will distribute cash dividends 3.0 yuan (including tax) per 10 shares, and the total amount of cash dividends to all shareholders registered on the equity registration date will be , 225,148.40 yuan (tax included).

2018 year will not carry out provident fund to increase share capital.

2. Profit Distribution Plan Description

( 1 ) Implementation of the Company's Cash Dividend Policy

The Articles of Association of the Company stipulate that the accumulated profits distributed in cash in the last three years shall not be less than the 30% of the average annual distributable profits realized in the last three years.

The proportion of the company's accumulated profits distributed in cash in the last three years to the average annual distributable profits realized in the last three years is 89.59 , which is in line with the cash dividend policy stipulated in the company's "Articles of Association.

( 2 ) Company's Development

At present, the company is in the stage of accelerated development. The company will speed up the project of Guizhou Huangpinggu Longmingchuan Cement Co., Ltd. On the basis of acquiring the 100% equity of the company, the company will continue to invest about 6.5 .3 billion yuan to build a new dry cement production line with a daily output of of 4500 tons of cement clinker (with waste heat for power generation); the total investment for the project of producing 20 .7 billion solid preparations in Jinxi production base of Jianfeng pharmaceutical industry with an annual output of is expected to be 50146 .49 million yuan, and 2019 will carry out plant construction and equipment procurement. Anhui Zhongwang, a subsidiary of Shanghai Beika, a subsidiary of Jianfeng Pharmaceutical Company, will carry out the second phase of technological transformation to build an intermediate and bulk drug base for the company's pharmaceutical sector. In addition, spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor new drug "DPT " has entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. The development of the above-mentioned business requires large financial support.

( 3 ) Considering that the company has invested a lot in technological transformation and new product development in 2018 , in order to maintain the company's stable operation and support the company's long-term development, Taking into account the short-term and long-term interests of shareholders, the board of directors approved the above-mentioned 2018 profit distribution plan.

( 4 ) The company will hold a 2018 annual performance and cash dividend explanation meeting to communicate and exchange with investors on the company's 2018 annual performance and cash dividend matters, and timely answer investors' concerns.

3. Review Procedure

2019 4 26 , the company held the 184 meeting of the 10th 183 of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on his behalf, comply with the relevant provisions of the "Company Law" and the "Articles of Association" of the company, and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the company's 2018 profit distribution plan was deliberated and approved with 9 votes in favor, 0 votes against, and 0 abstentions.

The board of directors intends to submit the plan to the

2018 Annual General Meeting of Shareholders for deliberation. When the company convenes the general meeting of shareholders, it will provide investors with online voting facilities.

4. Independent Director Opinion

The independent director of the company expressed the following opinions on the profit distribution plan of the company

2018 :

, and the independent director agreed that the company should use 2018 year-end share capital ,344,083, 828 as the base, A cash dividend of 3.0 yuan (tax included) will be distributed to 10 shares of , and the total amount of cash dividends distributed to all shareholders registered on the date of equity registration is ,148.40 yuan (tax included), No provident fund will be converted into share capital in 2018 .

. The profit distribution plan is formulated according to the actual operating results and financial situation of the company 2018 , and in combination with the actual needs of the company's future business development. The retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company and the long-term interests of shareholders, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors believe that the plan complies with the relevant provisions of the Company's Articles of Association on profit distribution and the actual operating conditions of the Company.

3 , the company's board of directors considered and approved the above profit distribution plan. The independent directors believe that the convening, convening, and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the "Articles of Association", and are legal and effective; and agree to submit the plan to the company's 2018 Annual General Meeting for deliberation.

5. Related Risk Tips

This profit distribution plan must be submitted to the company's 2018 annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

April 30, 2019

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页